Haematological Malignancies Clinical Trial
Official title:
A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
The purpose of the study is to the evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of AZD0466 as monotherapy in partciapants with advanced haematological malignancies and also to assess drug-drug interaction (DDI) potential between AZD0466 and the azole antifungal voriconazole.
The study consists of 2 individual modules as: Module 1 (AZD0466 monotherapy), and Module 2 (DDI study of AZD0466 with voriconazole). Eligible participants will be assigned to study treatments across Modules 1 and 2. 1. Module 1: AZD0466 monotherapy will include 2 parts- Part A dose escalation cohorts and Part B dose expansion cohorts. Initiation of Part B will depend on the evaluation of safety, tolerability, and PK in Part A. 2. Module 2: AZD0466 and voriconazole DDI study. All participants will receive AZD0466, and administration will continue until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01719341 -
Study of Non-Myeloablative Haplo-identical Haematopoietic Stem Cell Transplantation in Patients With Haematological Malignancies or Acquired Aplastic Anaemia
|
N/A | |
| Completed |
NCT01827579 -
Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)
|
Phase 1/Phase 2 | |
| Suspended |
NCT02988258 -
Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT
|
Phase 1 | |
| Completed |
NCT05148806 -
Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies
|
||
| Terminated |
NCT01080664 -
A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies
|
Phase 1 | |
| Withdrawn |
NCT01336478 -
CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation
|
Phase 1 |